Search

2 days ago
Dana-Farber Cancer Institute investigators describe a personalized cancer vaccine trial in kidney cancer that was published in Nature. All nine patients did not see their cancer recur.
Toni Choueiri and Patrick Ott describe how this peptide-based vaccine was peronalized to dozens of the patient's neoantigens in this this ad

4 days ago
One Canal by Breakthrough - Ready for immediate occupancy in Cambridge, MA
Biotech companies looking for office and lab space in the heart of Cambridge, look no further. One Canal by Breakthrough , on First...

5 days ago
Biotech CEO Sisterhood: Avidity Biosciences' CEO Sarah Boyce discusses a leader's responsibility to address dysfunction and the importance of corporate culture
Interviewed by Sisterhood editorial board member Sheila Gujrathi, Sarah Boyce describes how to recognize dysfunction and the importance...

Jan 29
Cambridge, UK based LoQus23 Therapeutics will use a small molecule allosteric inhibitor of MutSβ to treat Huntington's
Co-Founder and CEO David Reynolds describes why LoQus23 is taking a small molecule approach to neurodegenerative diseases and why they...

Jan 29
Cambridge, UK based Harness Therapeutics, which topped up its seed financing this week, aims to use its oligo platform to treat Huntington's by upregulating the FAN1 nuclease across the brain
CEO Jan Thirkettle describes the company's approach to upregulating genes for neurodegenerative diseases and how Harness is out front in...

Jan 27
Akero's CEO comments on today's 96 week MASH data and the future of efruxifermin
Andrew Cheng describes the F4 patient population, and dicusses the efficacy and safety data Akero saw today. Plus, ongoing trials and how...


Jan 27
BioVenture VoiCes Episode 11: Pillar VC's Tony Kulesa
A Partner at Pillar VC, Tony describes his start at MIT, founding the MIT BioMakerspace, his work at Petri, being an early supporter of...

Jan 22
The co-founder of the Scientific Citizenship Initiative discusses the importance of scientific communication, and trying to place STEM PhDs into the Mass. State House as full-time policy advisors
In a discussion with gene editing technology expert TJ Cradick, Scientific Citizenship Initiative Co-Founder and Co-Director Daniel...

Jan 22
IntraBio, which moved from Oxford, UK to Austin, Texas last year, received FDA approval in September for its modified amino acid, AQNEURSA, to treat neurological manifestations of Niemann-Pick type C
President and CEO Professor Mallory Factor KCNG describes the mechanism of the therapy and the company's commercial launch and hiring....

Jan 21
Biotech CEO Sisterhood: Mary Lynne Hedley shares advice on board makeup, running meetings, and other factors into having an effective board of directors
Interviewed by Sisterhood editorial board member Julia Owens, Dr. Hedley, who was the co-founder of TESARO and today is a member of...

Jan 16
Off Target Effects Episode 1: From SF Healthcare Week, Matt interviews Brad Loncar about M&A and China's potential impact on it
For the first episode of the new video podcast, Matt turns the tables on Brad Loncar and interviews him about his experiences and...

Jan 16
SF Healthcare Week: Cytokinetics CEO Robert Blum describes preparing for the potential commercial launch of aficamten, an upcoming monotherapy trial readout, omecamtiv mecarbil, and more
He highlights the company's current clinical programs, and talks about how thy are leveraging for the future the unique expertise in...

Jan 16
SF Healthcare Week: Nicole Paulk shares an update on her company Siren Biotechnology and describes what the environment is like for smaller companies in biotech right now
She describes how Siren is being built with a universal AAV platform, and is nearing its first IND in oncology. Plus, the fundraising...

Jan 16
SF Healthcare Week: The Co-Founder and CEO of Kardigan talks about this week's $300M series A financing to do precision medicine for cardiovascular disease
Tassos Gianakakos describes the round and the investors who participated in it, and hints at the personalized, biomarker driven approach...

Jan 15
SF Healthcare Week: Recursion Co-Founder & CEO Chris Gibson talks the Exscientia merger, Recursion's scale and capabilities, and key targets in development
He discusses the merger that completed towards the end of last year, Recursion's computational and wet lab abilities, cerebral cavernous...

Jan 15
SF Healthcare Week: The CEO of Ionis talks about over 30 years of developing RNA therapies, and a new chapter as a commercial forward company
Brett Monia discusses the approval of TRYNGOLZA and an important data readout this year in severe hypertriglyceridemia. Plus, the...

Jan 15
SF Healthcare Week: Biohaven CEO Vlad Coric talks degraders, ion channel programs, and ADCs
He describes updates given for the degrader programs targeting IgG, IgA nephropathy, and peripartum cardiomyopathy.. Plus, ion channel...

Jan 15
SF Healthcare Week: Rachel Haurwitz shares an update on Caribou Biosciences' allo CAR-T programs in NHL, multiple myeloma, and lupus
She describes how the company's HLA matching and CD19 relapse testing is playing out, when we can expect to see new data, and how the...

Jan 15
SF Healthcare Week: The CEO of Arvinas talks protein degradation, including about the industry's first phase 3 readout that is upcoming this quarter
John Houston describes what he believes are the keys to protein degradation, and discusses the company's monotherapy and combination...

Jan 14
SF Healthcare Week: After striking a transformational deal with Sanofi, Novavax is ramping up its vaccine pipeline
CEO John Jacobs describes the Sanofi deal, and combining Covid vaccines with flu vaccines. Plus, how the company is thinking about...